Delaware has become the latest US state to pass a law allowing substitution of a biosimilar for an originator biological, but with certain restrictions.
Delaware passes biosimilars substitution law
Home/Policies & Legislation
|
Posted 25/04/2014
0
Post your comment

The Delaware State Senate passed Senate Bill 118 (DE SB118) by a unanimous vote (21 to 0) on 9 April 2014.
The bill allows pharmacists to substitute US Food and Drug Administration (FDA) approved interchangeable biosimilars for prescribed biological reference products if the prescribing physician has not expressly prohibited substitution. The law also requires that the pharmacist records information on the label and dispensation record, informs the patient of the substitution and notifies the physician, in writing or electronically, within 10 days of the substitution. The pharmacy must also maintain a written or electronic record of any such substitutions for three years.
The Biotechnology Industry Organization (BIO), which represents originator biologicals companies, and the non-profit trade association Delaware BioScience Association (Delaware Bio) issued a statement in support of the legislation. The groups agree that the bill ‘ensures transparency and communication between patients and their treatment teams’ and ‘includes transparent communication on all biologic[al] medicines dispensed in order to maintain a consistent and complete medical record’.
The Generic Pharmaceutical Association (GPhA) has pointed out, however, that such laws are in conflict with the Biologics Price Competition and Innovation (BPCI) Act of 2009, which FDA ‘expressly states that an interchangeable biological product may be substituted for the reference product without the intervention of the healthcare provider’. Given the fact that FDA is yet to issue final guidance or receive a biosimilars application, GPhA also believes that laws concerning biosimilar substitution are ‘premature and unnecessary at this time’ [1].
Related articles
Indiana biosimilars substitution bill becomes law
California governor vetoes biosimilars bill
Reference
1. Derbyshire M. US state legislation on biosimilars substitution. Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(3):155-6. doi:10.5639/gabij.2013.0203.040
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.
Source: BIO,Delaware State Senate
Guidelines
Canada poised to remove requirement for Phase III trials for biosimilars
European position paper on AI in medicinal product lifecycle
Reports
Regulating biosimilars in Argentina: ANMAT’s approach
China-to-West pharma licensing deals surge in 2024 amid innovation push
DIGEMID’s 45-day auto-approvals trigger safety warning

Home/Policies & Legislation Posted 30/06/2025
ANVISA and Danish Medicines Agency renew health regulatory collaboration

Home/Policies & Legislation Posted 06/05/2025
Colombia and Brazil introduce reforms to enhance healthcare regulation

Home/Policies & Legislation Posted 22/04/2025
Second wave of drugs selected for Medicare price negotiation

Home/Policies & Legislation Posted 11/04/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment